Clinical trial
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous…
NCT00210340 · International Extranodal Lymphoma Study Group (IELSG), Other · Withdrawn
Key facts
| NCT number | NCT00210340 |
|---|---|
| Title | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis |
| Official title | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, B Cell |
| Intervention type | Drug |
| Interventions | intrathecal rituximab |
| Enrollment | 0 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 30, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: